MannKind Corp is a biopharmaceutical company with a unique business model. The company focuses on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. MannKind Corp is known for its technosphere-based inhalation technology, which allows for the delivery of therapeutic molecules through inhalation. This technology has been utilized in the development of their flagship product, Afrezza, an inhaled insulin for diabetes management. By leveraging innovative inhalation technology, MannKind Corp aims to provide effective and convenient treatment options for patients suffering from various diseases.

MannKind Corp is primarily active in the biotechnology and pharmaceutical industries.

Some of the main competitors of MannKind Corp in the market include Novo Nordisk, Eli Lilly and Company, and Sanofi. These companies also specialize in the development and commercialization of pharmaceutical products. However, MannKind Corp differentiates itself through its proprietary Technosphere® platform and its focus on delivering inhalable therapeutics.

MannKind Corp, a leading pharmaceutical company, has achieved several significant milestones. Firstly, they successfully developed and received approval for their flagship product, Afrezza, an inhalable insulin therapy for diabetes patients. This innovative treatment provides a convenient alternative to traditional injectable insulin. Additionally, MannKind Corp has secured key partnerships with pharmaceutical giants, such as Sanofi, to market and distribute Afrezza globally. The company has also made great strides in the research and development of Technosphere-based therapies, expanding their product portfolio. With their pioneering advancements, MannKind Corp continues to revolutionize diabetes management and strive for enhanced patient outcomes.

MannKind Corp is primarily present in the United States.

MannKind Corp is a pharmaceutical company committed to improving the health and well-being of people. With a strong corporate philosophy focused on innovation and patient-centricity, MannKind Corp prioritizes developing advanced therapies that address unmet medical needs. The company specializes in inhalation therapies for diseases such as diabetes and pulmonary hypertension. MannKind Corp's values revolve around integrity, compassion, and scientific excellence, driving its mission to deliver life-changing treatments. By pushing the boundaries of science and prioritizing patient outcomes, MannKind Corp aims to make a positive impact on global healthcare.

Analysts currently set an average price target of 9,80 USD for the MannKind stock (median: 10,20 USD), implying +150,7 % versus the latest price. The consensus is based on 15 analyst ratings.

MannKind Analyytikkojen kursstavoitteet 2026

15 analysts currently rate the MannKind stock: 14 recommend buying, 1 holding and 0 selling. For 2026, analysts expect MannKind to generate revenue of 463,02 M USD and earnings per share of −0,02 USD.

MannKind Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the MannKind share trades at 3,40 EUR (3,91 USD).

The MannKind share (MNKD) is listed on 5 stock exchanges, including: NASDAQ (MNKD), Frankfurt (NNFN.F), München (NNFN.MU), Düsseldorf (NNFN.DU), SIX (Zürich) (NNFN.SW).

The MannKind Corporation is a biopharmaceutical company based in the USA. The company specializes in the development and marketing of therapeutics for various diseases, particularly respiratory diseases. MannKind's business model is based on innovative technologies that help improve the effectiveness and safety of respiratory disease treatment. The company particularly offers the drug Afrezza, which was developed using the technology of fine moisture particles (Technosphere). The principle of action is that instead of traditional injections, insulin is administered directly to the lungs through inhalation and absorbed into the bloodstream from there. This allows for rapid action and dispensing of insulin without the need for needles. MannKind's main focus is currently on the approval and marketing of Afrezza. The drug is intended to provide an alternative to insulin injections for patients with type 1 and type 2 diabetes mellitus. MannKind acts as a licensor and also collaborates with the pharmaceutical giant Sanofi. Sanofi is allowed to introduce the medication into European and global markets. In addition to Afrezza, MannKind is also active in the development of treatment options for other respiratory diseases such as asthma. The company is working on developing further technologies to make the treatment of these diseases more effective and safer. In addition to their core competence in the field of respiratory diseases, MannKind also invests in the development of products based on their proprietary technologies. Through various research projects and partnerships with other companies, MannKind seeks to apply their technologies in other areas as well. It can be assumed that MannKind has a high interest in protecting their technologies through intellectual property. Patents and licenses are intended to secure the knowledge behind them and protect the investment in the research of future medications. Overall, the MannKind Corporation seems to be a company with great potential. Their business model is based on innovative technologies for the treatment of respiratory diseases and they position themselves as licensors and partners. Another focus is on the development of products based on their technologies. If Afrezza is successfully marketed, MannKind could become an important player in the market, benefiting from their intellectual property and technologies.

odotettu liikevaihto MannKind on 463,02 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto MannKind on −4,71 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

MannKind:n hinta-voitto-suhde (P/E) on tällä hetkellä −260,67. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan MannKind-osakkeen arvostusta.

MannKind:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,65. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii MannKind-osakkeen arvostuskennuslukuna.

MannKind:n Eulpool-laatuscore on 4/10.

MannKind:n ISIN on US56400P7069. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

MannKind:n WKN on A2DMZL. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

MannKind:n ticker on MNKD. Tämä pörssinoteeraus käytetään MannKind-osakkeiden kauppaan pörssissä.

MannKind maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

MannKind kuuluu sektoriin 'Terveydenhuolto'.

MannKind:n osingot jaetaan valuutassa USD.